Research from the University of Zurich and the University Hospital of Psychiatry, Zurich, suggests that because genetic risk ...

The occurrence of violence in the presence of mental illness has contributed to the stigma against people with psychiatric ...

A former 20-year state legislator, mental health advocate and author shared a powerful story of navigating her son’s ...

The comprehensive meta-analysis found that individuals with early-onset disorders characterized by language impairments — such as autism, schizophrenia and dyslexia — are significantly more likely to ...

He has learned to love just about every genre of game that exists. Our Blue Prince guide will show you how to get the Paper Crown in the Closed Exhibit and where to find the clues you need to do it.

Earlier this year, scientists discovered a peculiar term appearing in published papers: "vegetative electron microscopy". This phrase, which sounds technical but is ...

Manchester United are considering a shock swoop for Manchester City star James McAtee. Arsenal are confident of making Real Sociedad's Martin Zubimendi their first signing of the summer - despite ...

Former DGP Om Prakash wife Pallavi is reportedly suffering from schizophrenia. Schizophrenia is a serious mental illness. However, many people suffering from this disease do not even know that ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year.

A new, closely watched schizophrenia medication from Bristol Myers Squibb sold well in its first full quarter on the market, according to both the company and analysts. In its latest earnings report, ...

A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in decades has failed a pivotal test intended to support expanding its use ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...